ArticleACS medicinal chemistry letters2023

PROTAC: Harnessing Targeted Chimeras for Selective BCL-2 Degradation in Cancer Treatment.

Robert B KargboPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.